Photo from wikipedia
Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. We aimed to develop a population (pop)PK/PD model to… Click to show full abstract
Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. We aimed to develop a population (pop)PK/PD model to characterise the infliximab dose–exposure–biomarker–response (faecal calprotectin [fCal] and endoscopic remission [ER]) relationship.
Keywords:
faecal calprotectin;
infliximab;
exposure;
crohn disease;
patients crohn;
endoscopic remission
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!